Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial

Autor: Cláudia S. Ferreira, Galina Babitzki, Irina Klaman, Oliver Krieter, Katharina Lechner, Johanna Bendell, Suzana Vega Harring, Florian Heil

Publikováno v: Frontiers in Oncology, Vol 13 (2023)

IntroductionAngiopoetin-2 (Ang-2) is a key mediator of tumour angiogenesis. When upregulated it is associated with tumour progression and poor prognosis. Anti-vascular endothelial growth factor (VEGF) therapy has been widely used in the treatment of

Externí odkaz: https://doaj.org/article/853678b68e134569808a0e71d37b5e1f

482 Phase1/2 study of an anti-galectin-9 antibody, LYT-200, in patients with metastatic solid tumors

Autor: Judy Wang, Filip Janku, Manish Sharma, Johanna Bendell, Amit Mahipal, George Dranitsaris, Aleksandra Filipovic, Zev Wainber, Joseph Bolen, Eric Elenko, Christopher Korth

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)

Externí odkaz: https://doaj.org/article/4030daa32d424f27810737f1dbfa79bc

495 Trial of SNX281, a systemically delivered small molecule STING agonist, in solid tumors and lymphomas

Autor: Judy Wang, Gerald Falchook, Johanna Bendell, Meghana Kulkarni, Melissa Johnson, Salah Nabhan, Peter Sandy, Ololade Dosunmu, Humphrey Gardner

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)

Externí odkaz: https://doaj.org/article/12c4c956982346648ad5d2b40da857fd

CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

Autor: Hendrik-Tobias Arkenau, Marta Gil-Martin, Fiona Thistlethwaite, Aung Naing, Karen A. Autio, Patrick A. Ott, Johanna Bendell, Patricia LoRusso, Valentina Boni, Alexander Spira, Javier Garcia-Corbacho, Mark Stroh, Elisabeth G.E. De Vries, Ferry A.L.M. Eskens, Nataliya Uboha, Manreet Randhawa, Greg Durm, Alison L. Hannah

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)

Background Probody® therapeutics are antibody prodrugs that are activated in the tumor microenvironment by tumor-associated proteases, thereby restricting the activity to the tumor microenvironment and minimizing ‘off-tumor’ toxicity. We report

Externí odkaz: https://doaj.org/article/e9995b5c481945709e7709fd5db97be9

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

Autor: John H Strickler, Andrea Cercek, Salvatore Siena, Thierry André, Kimmie Ng, Eric Van Cutsem, Christina Wu, Andrew S Paulson, Joleen M Hubbard, Andrew L Coveler, Christos Fountzilas, Adel Kardosh, Pashtoon M Kasi, Heinz-Josef Lenz, Kristen K Ciombor, Elena Elez, David L Bajor, Chiara Cremolini, Federico Sanchez, Michael Stecher, Wentao Feng, Tanios S Bekaii-Saab, Marc Peeters, Marc Van den Evnde, Christophe Borg, Matthieu Sarabi, Francois Ghiringhelli, Benoist Chibaudel, Maria G. Zampino, Susana R. Keranen, Ramon Salazar, Pilar Alfonso, John H. Strickler, Andrew S. Paulson, Joleen M. Hubbard, Andrew L. Coveler, Pashtoon M. Kasi, Kristen K. Ciombor, David L. Bajor, Tanios S. Bekaii-Saab, Olumide Gbolahan, Patrick Boland, Daniel Berg, Timothy Goggins, Anwar Saeed, Howard Burris, Johanna Bendell, Darryl Outlaw, Isaac Tafur, Ardaman Shergill, Daniel Catenacci, Jun Gong, Ignacio Garrido-Laguna, Gene Finley, Benjamin Weinberg, Anthony Shields, Philip Philip, Anita Turk, Anthony Nguyen, Fadi Braiteh, Vijay Patel, William Harwin, Ian Anderson, Ajay Kundra, Christopher Chen, James Ford, Madappa Kundranda, Danny Nguyen, Suresh Ratnam, Donald Richards, Sujatha Nallapareddy, Sridhar Beeram, Scott McKenney, Spencer Shao

Publikováno v: The Lancet Oncology. 24:496-508

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7adfd2ad44d4d2c2a9c7ef887cf177ac
https://doi.org/10.1016/s1470-2045(23)00150-x